entrectinib | Cancer Search

Details 29 Related Guidelines / Approvals

type

NCCN Guideline

nccn category

2A

biomarkers

biomarker

NTRK1 Fusion

biomarker

NTRK2 Fusion

biomarker

NTRK3 Fusion

condition

condition

Hepatocellular Carcinoma

settings

settings

Metastatic

settings

Subsequent line

settings

Unresectable

drugs

drug

entrectinib

drug types

drug

targeted therapy

references

link

Hepatobiliary Cancers (NCCN Guidelines) [1.2022]

source

NCCN

entrectinib

biomarker

ROS1 Fusion

condition

Non-Small Cell Lung Carcinoma

disease state

Metastatic

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Malignant Solid Tumor

disease state

Metastatic, +1 more state

therapeutic contexts

No standard/acceptable treatment, +1 more context

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Small Intestinal Adenocarcinoma

disease state

Metastatic

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

disease state

Metastatic, +1 more state

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Glioblastoma, +1 more condition

disease state

Recurrent

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Uterine Corpus Sarcoma

disease state

Metastatic, +1 more state

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Vulvar Squamous Cell Carcinoma

disease state

Advanced, +2 more states

therapeutic contexts

Second line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Non-Small Cell Lung Carcinoma

disease state

Advanced, +1 more state

therapeutic contexts

First line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Thyroid Gland Follicular Carcinoma

disease state

Advanced

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Cervical Carcinoma

disease state

Metastatic, +1 more state

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Gastric Adenocarcinoma

disease state

Locally advanced, +3 more states

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

entrectinib

biomarker

NTRK1 Fusion, +2 more biomarkers

condition

Pancreatic Adenocarcinoma

disease state

Locally advanced, +2 more states

therapeutic contexts

Subsequent line

drug

entrectinib

drug type

targeted therapy

29 therapies
Page 1 of 3